GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Chenguang Biotech Group Co Ltd (SZSE:300138) » Definitions » Piotroski F-Score

Chenguang Biotech Group Co (SZSE:300138) Piotroski F-Score : 2 (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chenguang Biotech Group Co Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chenguang Biotech Group Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Chenguang Biotech Group Co's Piotroski F-Score or its related term are showing as below:

SZSE:300138' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 9
Current: 2

During the past 13 years, the highest Piotroski F-Score of Chenguang Biotech Group Co was 9. The lowest was 2. And the median was 5.


Chenguang Biotech Group Co Piotroski F-Score Historical Data

The historical data trend for Chenguang Biotech Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chenguang Biotech Group Co Piotroski F-Score Chart

Chenguang Biotech Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 6.00 5.00 2.00

Chenguang Biotech Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 2.00 2.00

Competitive Comparison of Chenguang Biotech Group Co's Piotroski F-Score

For the Farm Products subindustry, Chenguang Biotech Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chenguang Biotech Group Co's Piotroski F-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Chenguang Biotech Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Chenguang Biotech Group Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 163.611 + 99.701 + 81.367 + 38.592 = ¥383 Mil.
Cash Flow from Operations was 818.41 + 313.074 + -1584.108 + 197.432 = ¥-255 Mil.
Revenue was 1850.835 + 1500.747 + 1702.071 + 1732.327 = ¥6,786 Mil.
Gross Profit was 199.825 + 200.263 + 165.931 + 142.192 = ¥708 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(7637.339 + 7239.853 + 7429.668 + 8539.58 + 9080.731) / 5 = ¥7985.4342 Mil.
Total Assets at the begining of this year (Mar23) was ¥7,637 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,181 Mil.
Total Current Assets was ¥6,910 Mil.
Total Current Liabilities was ¥4,297 Mil.
Net Income was 133.473 + 96.364 + 97.272 + 135.044 = ¥462 Mil.

Revenue was 1642.445 + 1569.105 + 1499.576 + 1817.862 = ¥6,529 Mil.
Gross Profit was 216.395 + 221.045 + 225.063 + 231.896 = ¥894 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(6173.267 + 6174.834 + 6500.629 + 6923.74 + 7637.339) / 5 = ¥6681.9618 Mil.
Total Assets at the begining of last year (Mar22) was ¥6,173 Mil.
Long-Term Debt & Capital Lease Obligation was ¥774 Mil.
Total Current Assets was ¥5,651 Mil.
Total Current Liabilities was ¥3,312 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chenguang Biotech Group Co's current Net Income (TTM) was 383. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chenguang Biotech Group Co's current Cash Flow from Operations (TTM) was -255. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=383.271/7637.339
=0.05018384

ROA (Last Year)=Net Income/Total Assets (Mar22)
=462.153/6173.267
=0.0748636

Chenguang Biotech Group Co's return on assets of this year was 0.05018384. Chenguang Biotech Group Co's return on assets of last year was 0.0748636. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Chenguang Biotech Group Co's current Net Income (TTM) was 383. Chenguang Biotech Group Co's current Cash Flow from Operations (TTM) was -255. ==> -255 <= 383 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=1180.523/7985.4342
=0.14783454

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=773.985/6681.9618
=0.115832

Chenguang Biotech Group Co's gearing of this year was 0.14783454. Chenguang Biotech Group Co's gearing of last year was 0.115832. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=6909.62/4297.453
=1.60784074

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=5651.299/3312.103
=1.70625702

Chenguang Biotech Group Co's current ratio of this year was 1.60784074. Chenguang Biotech Group Co's current ratio of last year was 1.70625702. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Chenguang Biotech Group Co's number of shares in issue this year was 532.303. Chenguang Biotech Group Co's number of shares in issue last year was 532.716. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=708.211/6785.98
=0.10436385

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=894.399/6528.988
=0.13698892

Chenguang Biotech Group Co's gross margin of this year was 0.10436385. Chenguang Biotech Group Co's gross margin of last year was 0.13698892. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=6785.98/7637.339
=0.88852675

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=6528.988/6173.267
=1.05762281

Chenguang Biotech Group Co's asset turnover of this year was 0.88852675. Chenguang Biotech Group Co's asset turnover of last year was 1.05762281. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+0+0+1+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chenguang Biotech Group Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Chenguang Biotech Group Co  (SZSE:300138) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Chenguang Biotech Group Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Chenguang Biotech Group Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chenguang Biotech Group Co (SZSE:300138) Business Description

Traded in Other Exchanges
N/A
Address
Number 1 Chenguang Road, Hebei Province, Quzhou, CHN, 057250
Chenguang Biotech Group Co Ltd is engaged in the processing of agricultural products and herb extracts in China. Its products include natural colors, including paprika oleoresin, marigold oleoresin, curcumin, red rice red, red cabbage, and red beet; and natural spice extracts and essential oils, such as capsicum oleoresin, zanthoxylum oil and oleoresin, black pepper oil and oleoresin, ginger oil and oleoresin, turmeric oil, star anise oil and oleoresin, cumin oil and oleoresin, garlic oil and oleoresin, and common fennel oil and oleoresin.
Executives
Li Feng Fei Executives
Zhou Jing Directors, Directors, and Executives
Li Yue Zhai Director
Lian Yun He Executives
Chen Yun Xia Executives
Zhao Tao Supervisors
Yuan Xin Ying Supervisors
Liu Zhang Lin Independent director
Lu Qing Guo Directors, executives
Zhou Fang Sheng Independent director
Wang Shu Hong Independent director
Liu Ying Shan Director
Han Wen Jie Executives
Liu Dong Ming Supervisors
Yang Wen Fang Supervisors

Chenguang Biotech Group Co (SZSE:300138) Headlines

No Headlines